Picture [iito] Fighting Customers 650x80px
Document › Details

Anocca AB. (7/22/21). "Press Release: Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy". Södertälje.

Organisations Organisation Anocca AB
  Organisation 2 Danske Bank A/S
  Group Danske Bank (Group)
Products Product TCR engineering technology (T-cell receptor engineering technology)
  Product 2 venture capital
Index term Index term Anocca–SEVERAL: investment, 202107 financing round Series B SEK400m ($47m) led by Danske Bank
Persons Person Jarvis, Reagan (Anocca 202107 CEO + Co-Founder)
  Person 2 Farmery, Mark (Anocca 202107 VP Business Development)

Financing from renowned Nordic investors

Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials.

The financing, led by advisor Danske Bank, brings together a distinguished group of investors, with Swedbank Robur Ny Teknik, Ramsbury Invest and significant family offices including those of Harald Mix and Robert Andreen joining existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.

Anocca’s CEO and co-founder Reagan Jarvis, said, “This financing round, which takes us to well over $100m raised since our founding in 2014, is further strong endorsement of our pioneering approach to industrialised high-precision analysis of T-cell biology. The team has built and operationalised an industry-leading suite of unique technologies to generate efficient and systematic TCR-T cell therapy pipelines. We will use this substantial financing to accelerate our broad oncology pipeline into the clinic with our in-house manufacturing capabilities. We continue to methodically move towards our vision of delivering blockbuster franchises of next generation T-cell immunotherapies for the treatment of multiple cancer types.”

The company’s highly industrialised cellular biology platform replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders. The technology platform is comprised of a number of proprietary cell biology and molecular genetics technologies and enables the scalable high-precision analysis needed to develop highly targeted therapeutics that leverage T-cell immunity. The platform is underpinned by proprietary, fully integrated, information management and bioinformatic software tools developed in-house.

Anocca’s platform has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer.

Anocca’s Chairman of the board and early investor, Hans Stra°berg said, “To deliver on the potential of new technologies you need to have the infrastructure in place to secure scaling. This is exactly what we have done with Anocca, by taking a systematic approach to building a broad industrialised platform with extensive automation and software tools, in addition to our own cGMP manufacturing facility, allowing us to drive multiple clinical programmes in parallel. This is an outstanding success for European life sciences, with Anocca emerging as a global scientific and technical leader in the field of TCR-T cell immunotherapy.”

Lars Hevreng, Financial Advisor at Danske Bank said, “We are delighted to bring together a distinguished syndicate of investors to back Anocca’s further development. The company’s long-term and very strong financial backing will now become even stronger, which will be very important for Reagan and his team to fully pursue their ambitious targets of unlocking the therapeutic potential of Anocca’s TCR-T cell immunotherapy approach.”

Media contacts:

Vice President Business Development
Mark Farmery

Scius Communications (for international media)
Katja Stout

Daniel Gooch

Cord Communications (for Swedish and Nordic media)
Mikael Widell

About Anocca

Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company’s innovative ‘engineered immunity’ approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of blockbuster assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic.

Anocca was founded in 2014 and is led by an experienced management team that has raised over USD 100 million in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco and Michano with Danske Bank acting as advisor. Anocca’s team of over 65 employees operates from its site in Södertälje, Sweden. To learn more about Anocca, please visit and follow our LinkedIn.

Record changed: 2021-10-22


Picture EBD Group BIO-Europe 2021 Time to Register 650x200

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Plain Stupid Simple 650x80px

» top